新药,HMTM, 可能得到国民保健体系的批准, 以减缓阿尔茨海默氏症, A new pill, HMTM, may be approved by the NHS to slow Alzheimer's, after showing promise in preventing tau protein clumps.

由英国TaurX公司研制的名为HMTM的日新药 " HMTM " (HMTM),可能获得批准,供国民保健系统使用,以减缓阿尔茨海默氏病的发育。 A new daily pill called Hydromethylthionine mesylate (HMTM), developed by British firm TauRX, may be approved for use by the NHS to slow Alzheimer's progression. 临床预科研究表明,它能防止与认知衰落有关的 Tau蛋白质凝聚物。 Preclinical studies show it prevents tau protein clumps linked to cognitive decline. 4月,监管者将决定是否应在国民保健制度上提供该药片,因为该药片可在痴呆病治疗方面取得重大进展。 Regulators will decide in April if the pill, which could offer a major advancement in dementia treatment, should be made available on the NHS.